Driehaus Capital Management LLC Has $118.02 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Driehaus Capital Management LLC increased its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,605,310 shares of the company's stock after purchasing an additional 71,703 shares during the period. Apogee Therapeutics makes up 1.0% of Driehaus Capital Management LLC's portfolio, making the stock its 16th largest holding. Driehaus Capital Management LLC owned about 5.79% of Apogee Therapeutics worth $118,021,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Optimize Financial Inc bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $203,000. Aigen Investment Management LP purchased a new stake in shares of Apogee Therapeutics in the 4th quarter valued at $216,000. BNP Paribas Financial Markets purchased a new stake in shares of Apogee Therapeutics in the 4th quarter valued at $219,000. Commonwealth Equity Services LLC acquired a new stake in Apogee Therapeutics during the fourth quarter valued at $222,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Apogee Therapeutics during the fourth quarter valued at $226,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at $38,983,558.05. This represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Carl Dambkowski sold 1,590 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20. Following the completion of the sale, the insider now directly owns 251,033 shares of the company's stock, valued at $7,651,485.84. The trade was a 0.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,175 shares of company stock worth $587,191. Insiders own 36.10% of the company's stock.

Apogee Therapeutics Trading Up 6.1%

Shares of Apogee Therapeutics stock traded up $2.29 during mid-day trading on Monday, hitting $39.58. 705,487 shares of the stock were exchanged, compared to its average volume of 526,393. The company has a 50-day simple moving average of $36.26 and a 200 day simple moving average of $41.51. Apogee Therapeutics, Inc. has a twelve month low of $26.20 and a twelve month high of $63.50. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -16.36 and a beta of 1.70.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24. Equities research analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on APGE shares. Wedbush reissued an "outperform" rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Citigroup began coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price target for the company. Finally, Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $94.60.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.